{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260602549826/en/Lantern-Pharma-Reports-HARMONIC%E2%84%A2-Data-Showing-LP-300-Progression-Free-Survival-Benefit-Deepens-with-Treatment-Duration-in-EGFR-Exon-21-L858R-Lung-Cancer", "message": "News view counter 773317 successfully enlarged"}